Triomics banks $22M to automate cancer chart review
Key insights
- Triomics grew ARR tenfold and enterprise customers fourfold in one year, now serving Memorial Sloan Kettering, MD Anderson, Yale, and Mount Sinai.
- A Nature Digital Medicine study confirmed 67% faster chart review and 40% better clinical trial match rates against standard oncology workflows.
- Battery Ventures led the round alongside Lightspeed and Y Combinator, pushing total Triomics funding past $36M.
Why this matters
Oncology sits at the intersection of the most document-heavy medical specialty and the highest-stakes treatment decisions, making AI-driven chart abstraction a genuine productivity lever with peer-reviewed, quantified outcomes rather than vendor-supplied claims. The tenfold ARR growth with a customer list of top-five NCI-designated cancer centers demonstrates that vertical AI can win enterprise procurement before horizontal EHR incumbents replicate the functionality inside existing contracts. For technical leaders evaluating build-vs-buy in healthcare AI, Triomics establishes the pattern: narrow-domain training data plus clinical validation plus inside-the-tent distribution investors can outrun generalist platform expansion for at least one product cycle.
Summary
Triomics closed a $22M Series B to deepen its oncology AI platform across elite cancer centers, with Battery Ventures leading and Lightspeed, Y Combinator, and Precision Health Informatics rounding out the round.
The platform targets the three most time-intensive administrative layers in oncology: chart abstraction, clinical trial matching, and visit preparation. A Nature Digital Medicine peer-reviewed study put the measured lift at 67% less chart review time and 40% better trial match rates. Current enterprise customers include Memorial Sloan Kettering, MD Anderson, Yale Cancer Center, and Mount Sinai.
Essentially: (Triomics, Battery Ventures) are betting that oncology is a durable vertical wedge before Epic, Oracle Health, or Microsoft consolidates it.
- ARR grew tenfold and enterprise customer count fourfold in the past year; total funding now exceeds $36M.
- Precision Health Informatics, a Texas Oncology subsidiary, joined as an investor, signaling a distribution-through-insiders strategy rather than a pure software sales motion.
- Peer-reviewed validation in a top journal is a deliberate credentialing move: academic medical centers require clinical evidence before procurement committees approve new vendors.
Potential risks and opportunities
Risks
- Epic, Oracle Health, or Microsoft could deploy equivalent chart abstraction features inside existing enterprise EHR contracts at near-zero marginal cost within 12 to 18 months, directly undercutting Triomics' pricing leverage at renewal.
- Investor Precision Health Informatics is a Texas Oncology subsidiary; if that relationship carries exclusivity obligations or preferred-vendor status, Triomics may face channel conflicts when targeting accounts served by competing GPOs or practice management groups.
- Peer-reviewed validation was conducted at large NCI-designated cancer centers with structured EHR environments; if abstraction accuracy degrades at community oncology practices with lower data quality, enterprise churn risk rises as the company scales beyond its current customer base.
Opportunities
- Clinical trial sponsors including Pfizer, Roche, and AstraZeneca could license or co-develop Triomics' trial-matching layer to accelerate enrollment pipelines, bypassing slower CRO-managed site outreach.
- Oncology-focused revenue cycle management vendors such as Navigant/Guidehouse and nThrive face displacement in chart abstraction workflows and have a narrow acquisition window before Triomics' valuation rises with its next round.
- Health system AI infrastructure platforms including Nuance/Microsoft DAX and AWS HealthLake gain a validated integration partner, with Triomics positioned as an API layer above EHR data that extends platform stickiness without requiring a full rebuild.
What we don't know yet
- Triomics' gross margins and pricing structure are undisclosed, making it unclear whether tenfold ARR growth reflects new logo volume, expansion revenue, or pricing power.
- Whether any of the named cancer center customers hold equity stakes or revenue-sharing arrangements that could create conflicts as Triomics expands to competing health systems.
- The terms of any integration agreements with Epic's Beacon oncology module or Oracle Health are not disclosed, leaving the EHR co-existence model unspecified.
Originally reported by hitconsultant.net
Read the original article →Original headline: Triomics Raises $22M Series B to Scale AI Automation Across Oncology Chart Review and Clinical Trial Matching at Elite Cancer Centers